Amryt Pharma, Proactis Holdings and PCF Group
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Amryt Pharma, Proactis Holdings and PCF Group
Joe Wiley, CEO of Amryt Pharma #AMYT discusses their $40m Private Placement with Leading Biotech Investors and how being listed on NASDAQ has increased interest in the company.
Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.
Tim Sykes, Chief Executive Officer at Proactis Holdings #PHD discusses the significance of signing its first contract for the provision of its accelerated payment service, bePayd.
Proactis creates, sells and maintains software and services which enable organisations to streamline, control and monitor all indirect expenditure. Its solutions are used in approximately 1,100 buying organisations around the world from the commercial, public and not-for-profit sectors.
(Interview starts at 11 minutes 9 seconds)
Scott Maybury, Chief Executive Officer of PCF Group #PCF talks about their preliminary results for the year and gives his outlook for a positive 2021.
Established in 1994, PCF Group plc is the AIM-quoted parent of the specialist bank, PCF Bank Limited. Since commencing operations as a bank in 2017, the Group has increased its lending portfolio from £140 million to over £430 million. The Group continues to focus on portfolio quality and lending to the prime segments of its existing markets. The Group will continue to identify opportunities to diversify its lending products and asset classes by setting up new organic operations or through acquisition.
(Interview starts at 16 minutes 13 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.